Strategic Transformation - The company is focusing on high-growth handheld markets aligned with opioid crisis response, defense budgets, and border security[9] - The company divested its biopharma desktop portfolio to REPLIGEN for $70 million in cash[11] - The company is targeting adjusted EBITDA profitability by Q4 2025 and cash flow positivity in 2026, driven by improved gross margins and streamlined operations[9] Financial Performance and Guidance - The company's revenue for the last twelve months as of June 30th was $54 million[15] - The company's cash balance as of June 30th was $119 million[15] - The company projects revenue from continuing operations to be between $54 million and $56 million in 2025, representing a year-over-year growth of +13% to +17%[43] - The company anticipates a return to 20%+ growth with defined catalysts[43] - The company's adjusted gross margin is expected to be in the mid-to-high 50% range[43] - Recurring revenue accounted for $9.1 million, or 37%, of total revenue in YTD 2025[45] Growth Catalysts - Equipment modernization, specifically replacing outdated FTIR devices, presents a 15,000-unit growth opportunity[40] - The launch of the next-generation MX908 device is expected to generate a replacement cycle[40] - The U S Department of Defense AVCAD program partnership represents a growth catalyst, with potential for >$10 million per year in revenue[40]

The results of operations data contained in this presentation are based on our preliminary, unaudited results of operations for the quarter ended June 30, 2025. Such preliminary data should not be viewed as a comprehensive statement of our financial results for the quarter ended June 30, 2025 CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS August 5, 2025 Disclaimers 2Q25 Earnings Presentation The forward-looking statements contained in this presentation are based on our current expectations and belie ...

Clear Channel Outdoor Holdings 2025 Second Quarter Results August 5, 2025 Safe harbor statement and other information Forward-Looking Statements Certain statements in this presentation are considered "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Clear Channel Outdoor Holdings, Inc. and its subsidiaries ( ...

Financial Performance Highlights - Broadridge's FY25 recurring revenue grew by 7% in constant currency[14] - Adjusted EPS grew by 11% in FY25[14] - Closed sales reached $288 million in FY25[14] - Q4'25 Recurring revenues were $1424 million, a 7% increase[23] - Adjusted EPS for Q4'25 was $355, a 1% increase[23] Segment Performance (Recurring Revenue) - ICS (Investor Communication Solutions) recurring revenues for FY25 were $2732 million, up 6%[25] - GTO (Global Technology and Operations) recurring revenues for FY25 were $1776 million, up 8%[28] - Capital Markets recurring revenue grew by 6% to $1115 million in FY25[28] - Wealth & Investment Management recurring revenue grew by 12% to $661 million in FY25[28] Growth Drivers and Future Outlook - Equity position growth was 16% in FY25[31] - Internal Trade Growth was 13% in FY25[31] - Broadridge expects 5-7% recurring revenue growth in constant currency for FY26[14] - Broadridge projects 8-12% adjusted EPS growth for FY26[14]

Company Overview - Armada Hoffler (AHH) is a vertically integrated REIT focused on developing, building, acquiring, and managing retail, office, and multifamily properties primarily in the Mid-Atlantic and Southeastern US[3] - The company's weighted average stabilized portfolio occupancy was 949% as of June 30, 2025[6] Financial Performance (Q2 2025) - Second Quarter Normalized FFO per diluted share was $025[6] - Net income attributable to AHH and OP Unitholders was $3907 thousand, or $004 per diluted share[11] - Total revenues reached $101263 thousand, with rental revenues contributing $65147 thousand and general contracting and real estate services revenues at $31976 thousand[13] 2025 Outlook - The company projects a property portfolio NOI between $1736 million and $1760 million[8] - Construction segment profit is expected to be between $50 million and $70 million[8] - Normalized FFO per diluted share is projected to be between $100 and $110[8] Debt and Leverage - Total debt outstanding as of June 30, 2025, was $1448237 thousand[11] - The company's stabilized portfolio debt to stabilized portfolio adjusted EBITDAre was 52x[11] - As of June 30, 2025, 938% of the company's debt was fixed-rate, with a weighted average interest rate of 44%[30, 31, 38]

Financial Performance - Onity Group Inc delivered strong second quarter results in 2025, with sustained robust net income driving book value growth[9, 10] - Diluted EPS increased by 35% year-over-year to $2.40, and book value per share increased by $2.94 year-over-year to $60[12] - The company reaffirmed its annual Adjusted ROE guidance of 16-18%, demonstrating a commitment to strong shareholder returns[10] - Adjusted Pre-Tax Income was $16 million in Q2'25[12] Servicing Portfolio - Total Servicing Average UPB grew to $307 billion[12, 21] - Owned Servicing Average UPB increased from $147 billion in Q1'25 to $153 billion in Q2'25[21] - MSR originations increased by 35% year-over-year, exceeding industry growth of 23%[23] Originations - Originations volume reached $9.4 billion in Q2'25[12, 24] - Consumer Direct funded volume increased by 2.4x year-over-year[26] - The company achieved a top-tier refinance recapture rate, 1.5x the industry average in Q2'25[26] Technology and Efficiency - The company is expanding its AI-powered platform to grow revenue, reduce costs, and drive service excellence[32] - Robotic Process Automation (RPA) is performing over 190 processes, completing the work of approximately 400 FTE[35]

Company Overview - Neuronetics and Greenbrook have combined to leverage scale and capabilities for mental health treatment[17] - The combined company has treated 221,376 unique patients[18] and administered 7,912,427 treatments[19] - The company reported $129 million in annual revenue for 2024 (pro forma adjusted)[19] Market and Opportunity - The total available market is 293 million U S adults and adolescents suffering from depression, depression with anxiety, and OCD[33,34] - Approximately 8 million patients are poorly served by antidepressant medication[34] - Better Me Program (BMP) clinics treat 33 times more patients than non-BMP clinics[57,58] Financial Performance and Guidance - Q2 2025 revenue was $381 million, a 132% increase from Q2 2024[90] - The company projects revenue between $149 million and $155 million for FY 2025, representing a 15% to 19% pro forma year-over-year growth[85] - The company anticipates achieving positive cash flow from operations in Q4 2025[85]

Financial Performance & Outlook - Q2 2025 revenue reached $193 million, a 9% increase compared to Q1 2025[11] - Home & Life revenue in Q2 2025 was $83 million[11, 14], representing a 45% year-over-year growth[15] - Industrial & Commercial revenue in Q2 2025 was $110 million[11, 18], a 25% year-over-year growth[18] - GAAP gross margin improved to 56.1% in Q2 2025, up from 55.0% in Q1 2025[22, 23] - Non-GAAP gross margin improved to 56.3% in Q2 2025, up from 55.4% in Q1 2025[22, 23] - GAAP loss per share was $(0.67) in Q2 2025, compared to $(0.94) in Q1 2025[26, 28] - Non-GAAP earnings per share improved to $0.11 in Q2 2025 from $(0.08) in Q1 2025, a 238% increase[27, 28] - Q3 2025 revenue is projected to be between $200 million and $210 million[6, 32] - The company forecasts a 15-25% revenue growth, which is 3x the semiconductor market growth rate[44] Market & Strategy - The company aims to be the undisputed leader in embedded wireless[8] - The company estimates the IoT market will reach >10 Billion devices per year by 2035[9]

Q2 2025 Financial Performance - Pro Forma Net Sales reached $2007 million, a 35% year-over-year increase on a constant currency basis[18, 27, 28] - Non-GAAP Pro Forma Adjusted EBITDA was $206 million, representing 103% of pro forma net sales, compared to $166 million in Q2 2024[18, 30] - Non-GAAP Pro Forma Adjusted Gross Margin improved to 727%, compared to 713% in Q2 2024[18, 30] - Free Cash Flow was $45 million, showing continued positive year-over-year progress[18] Segment Performance - Bone Growth Therapies (BGT) net sales increased by 6% year-over-year[18, 23] - U S Spine Fixation net sales grew by 5% year-over-year, driven by a 7% increase in U S procedure volume[18, 24] - U S Orthopedics net sales saw a significant increase of 28% year-over-year, marking the fourth consecutive quarter of double-digit growth[18] Future Outlook - The company expects to be free cash flow positive for the full year 2025[36] - Full-year 2025 guidance includes Pro Forma Net Sales of $808 million to $816 million and Pro Forma Adjusted EBITDA of $82 million to $86 million[38]

Financial Performance - Second Quarter 2025 revenue reached $64 million[6] - Payor revenue increased by 35% year-over-year[16] - Adjusted EBITDA grew nearly 100% year-over-year[16] - The company has approximately $103 million in cash and equivalents, including available for sale securities, with zero debt[16] - Approximately $14 million of shares were repurchased under the company's buyback plan[16] Business Growth & Innovation - Unique Active Payor Members increased by 25%, and Payor sessions grew by 29% year-over-year[15] - The company is partnering with AWS Generative AI Innovation Center to develop a Safety and Quality Model[15] - The company enhanced its suicide detection technology and expanded into areas like substance misuse and abuse or neglect[15] Partnerships & Expansion - The company deepened its relationship with Amazon by launching Amazon Pharmacy Integration[16] - The company expanded in women's health through a new partnership with Tia Health[16] - Several additional partners, such as Genomind, Bark, and Hinge, will integrate Talkspace into their ecosystem[16] Financial Guidance - The company maintains its revenue guidance of $220 million to $235 million, representing a 17% to 25% year-over-year increase[21] - The company maintains its Adjusted EBITDA guidance of $14 million to $20 million, representing a 101% to 187% year-over-year increase[22]